《新股表現》亞盛醫藥(06855.HK)暗盤收報52.1元 高上市價52.3%
根據輝立交易平台顯示,下周一(28日)掛牌的亞盛醫藥(06855.HK)暗盤高開逾16%報39.8元,最高見52.5元,收報52.1元,較上市價34.2元,高52.3%或17.9元,成交185萬股,涉資8,970元。不計手續費,每手100股,賬面賺1,790元。
亞盛是一間放眼全球的臨床階段生物科技公司,其主要從事開發治療癌症、乙型肝炎病毒(HBV)及衰老相關疾病的新型療法。是次來港上市合共發售1,218.09萬股,並已引入中生製藥(01177.HK)為基石投資者將認購458.64萬股;10%公開發售獲約751倍超購,已啟動回撥機制佔比增至50%,認購一手中籤率僅9%;股份以招股範圍(32.2-34.2元)上限定價,料集資淨額近3.12億元,其中42%將用於研發,將核心產品HQP1351商業化;餘下將用作APG-1252、APG-2575、APG-115、APG-1387及APG-2449其他臨床計劃的持續及規劃臨床試驗等。上市聯席保薦人分別為美銀美林及花旗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.